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(ROS) (14), which have been implicated in
a variety of toxic effects (15) including
cancer (initiation and promotion), espe-
cially in small rodents which have particu-
lar sensitivity to oxygen radical toxicity
(11,12). Chemicals that act as substrates
for other cytochromes P450 are, in general,
detoxified by these enzymes to polar
metabolites which are readily conjugated
and eliminated (10).
From a consideration of their molecu-
lar and electronic structures, chemicals
may be shown to exhibit specificity for one
or more of these cytochromes P450, and,
together with information relating to the
enzymes' active site dimensions, it is possi-
ble to accurately predict the P450 specifici-
ty of a test compound and its toxic out-
come. To predict the P450 isoform, it is
necessary to calculate certain molecular
and electronic structural characteristics, the
overall degree of planarity (area/depth2),
the molecular size (collision diameter), and
the likelihood of activation by oxygena-
tion, expressed as AE, the energy difference
between the lowest unoccupied and the
highest occupied molecular orbits [(AE =
E(LUMO) - E(HOMO); LUMO, lowest
unoccupied molecular orbit; HOMO, high-
est occupied molecular orbit]. Graphical
analysis ofthis information and comparison
with training set data for known cyto-
chrome P450 substrates and inducers,
including carcinogens and noncarcinogens,
leads to an overall prediction of potential
toxicity. This technique of COMPACT
(16,17) has been validated against 100
NTP chemicals of known carcinogenicity
and gave a concordance of 92% based on
specificity for P4501 and P4502E (17).
The COMPACT evaluation of the 40
NTP chemicals in the present study (18)
were compared with our own Hazardexpert
evaluations ofthe same chemicals and with
rodent carcinogenicity assays and Ames test
results previously published (19,20).
Methods
Molecular structural and electronic para-
meters for COMPACT analysis of the 40
NTP chemicals were determined as previ-
ously described (2,17,18). Criteria for
P450 substrates were a high degree of
molecular planarity (aid') and a high
potential for activation by oxidative
metabolism (AL) combined in the COM-
PACT ratio [CR = (aid2)1(AE- 8)]. In a
plot ofa/d2 against AE, those cytochrome
P4501 (CYPI) substrates with high values
of ad2and low values of AE (<15.0 eV)
are the most potent ofknown carcinogens
(1,9,10). The use of the term (AE - 8)
instead ofAE arises because 8 is approxi-
mately the lowest value of AE to be
obtained and is characteristic of a high
potential for activation by oxidative
metabolism. P4501 substrates are charac-
terized by values of CR >0.5, and this is
the criterion for the prediction (C1) of
carcinogenesis from P4501 activation.
The criterion for cytochrome P4502E
(CYP2E) substrates is a small value for the
molecular collision diameter (<6.5 A). A
low value ofAEwas also used as a criteri-
on because this gives an indication of the
ease ofactivation ofthe substrate. P4502E
substrates are believed to be carcinogenic
by 1) their propensity to stabilize P4502E
and to generate ROS, which are them-
selves carcinogenic per se, and 2) their
tendency to undergo metabolic activation
to reactive intermediates, which are proxi-
mate or ultimate carcinogens (12,17).
Hence the criteria for prediction of car-
cinogenesis from P4502E activation (C2F)
are values of molecular diameter <6.5 A
and AE <15eV. COMPACT predictions
of carcinogenicity are made from the
affinity for P4501 (C1), affinity for
P4502E (C2E), and ifeither or both give a
positive response, the overall response
(C.) is considered to be positive.
Data for the prediction ofmetal toxicity
resulting from compounds 7, 16 and 35
have been obtained from standard metal/ion
redox potentials and interpreted according
to a previously generated quantitative struc-
ture-activity relationship for metal toxicities
involving this parameter (3). It has been
shown that the acute toxicities ofabout 30
metal compounds after intraperitoneal
dosage to the mouse correlate (R = 0.86)
with the magnitude of the metal ion redox
potential. Hence, the respective redox
potentials are included for the three metal
compounds, from which an estimate oftheir
potential carcinogenicity has been made.
Ames mutagenicity and rodent car-
cinogenicity data are from Ashby and
Tennant (19,20). One positive response in
the four segments of the rodent assay is
taken as an overall "+" response. When
this single response is EE (equivocal evi-
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dence), the overall response is given as "±,"
but is taken as "-" in the final assessment.
Hazardexpert evaluations were made
using the standard software (version 6.1;
Compudrug Ltd., Budapest) (3,21).
Concordance evaluations are made
between COMPACT predictions (C) and
rodent carcinogenicity (1/4 segments posi-
tive) and between COMPACT plus
Hazardexpert and rodent carcinogenicity.
Results
The outcome of COMPACT analysis on
40 of the 44 test chemicals is shown in
Table 1 (18). COMPACT predictions
could not be made for 4 of these chemi-
cals, as three were inorganic (nos. 7, 16
and 35) and one was polymeric (no. 3).
Table 2 provides a comparison between
the COMPACT results with those of the
rodent two species bioassay, where it can be
seen that the rodent data for 4 chemicals
(nos. 12, 13, 18 and 34) remain to be com-
pleted. Thus, concordances with COM-
PACT and the NTP carcinogenicity results
can be made for only 36 chemicals. From
the point of view of identifying those
chemicals that are direct-acting, rather than
requiring metabolic activation, we have also
conducted EPA structural alert identifica-
tion for the 40 chemicals using the
Hazardexpert system (21). This software,
which is also rapid and inexpensive, runs
on the personal computer and also calcu-
lates logP and pK values which are general-
ly considered to be of potential value in
prescreening for toxicity. The results of
Hazardexpert determinations are presented
in Table 3 and combined concordances
with COMPACT predictions are shown in
Table 4.
The results ofCOMPACT and Hazard-
expert predictions are summarized in Tables
1-4, and these evaluations for each individ-
ual chemical are given in more detail to pro-
vide a rationale for concordances between
COMPACT and Hazardexpert predictions
and rodent assay results. The overall concor-
dance between COMPACT (P4501 and
P4502E) and rodent carcinogenicity is
72%, and the consideration of structural
alert evidence, provided by Hazardexpert,
improves the total agreement to 86%. p-
Nitrophenol (chemical no. 9), identified as
positive in both COMPACT and
Hazardexpert, but which is noncarcinogenic
in the rodent assay, is a polar compound,
which is readily conjugated and eliminated.
Chemicals regarded as negative by both
COMPACT and Hazardexpert (nos. 11, 17
and 21), but positive in the rodent assay,
were only weak or sex/species specific
rodent carcinogens; two of these (nos. 17
and 21) could be teratogenic via direct
interaction with DNA. These three chemi-
cals were all correctly identified as positive
Table 1. COMPACT data for prospective NTP studya
COMPACT prediction
Compound aIoM AE Diameter (A) CR C1 C2E CO
1. Amphetamine
2. Naphthalene
3. Polysorbate 80
4. Promethazine
5. Resorcinol
6. y-Butyrolactone
7. Manganese sulphate
8. Chloracetic acid
9. p-Nitrophenol
10. Tricresyl phosphate
11. o-Benzyl-p-chlorophenol
12. 2,2-Bis(bromomethyl)-
1,3-propranediol
13. t-Butanol
14. 3,4-Dihydrocoumarin
15. Ethylene glycol
16. Mercuric chloride
17. Methyl phenidate
18. Theophylline
19. 4,4'-Thiobis(6-t-butyl m-cresol)
20. Triamterene
21. Diphenylhydantoin
22. Pentachloroanisole
23. Chloramine
24. 4,4'-Diamino-2,2'-stilbene-
disulfonic acid
25. Methyl bromide
26. p-Nitrobenzoic acid
27. Sodium azide[hydrazoic acid]
28. Tris(2-chloroethyl)phosphate
29. Cl Direct blue 218
30. Cl Pigment red 3
31. Cl Pigment red 23
32. 2,4-Diaminophenol
33. 4-Hydroxyacetanilide
34. Salicylazosulfapyridine
35. Titanocene dichloride
36. Cl Acid red 14
37. Cl Direct blue 15
38. Coumarin
39. 2,3-Dibromo-l-propanol
40. 3,3'-Dimethylbenzidine
41. HC Yellow4b
42. p-Nitroaniline
43. o-Nitroanisole
44. 1,2,3-Trichloropropane
1.7
6.6
2.4
5.4
2.0
1.4
5.3
2.5
1.4
2.7
1.3
3.9
2.0
2.2
4.8
1.8
13.1
1.0
5.6
3.5
5.6
1.5
6.9
2.1
1.8
3.4
5.3
4.0
6.5
4.8
4.8
6.1
3.4
6.9
1.6
3.3
2.3
6.3
4.4
1.5
16.4
13.1
10.4
15.7
17.9
- E°
15.5
14.0
12.1
14.5
13.0
20.9
15.4
21.9
- E°
15.5
13.6
11.6
11.5
15.3
12.9
11.5
11.6
6.5
6.2
8.0
5.6
5.2
Mn/Mn2+
5.0
6.0
8.4
7.1
6.5
0.20 - - -
1.29 + + +
- NT NT NT
1.00 + - +
0.70 - - -
0.20 - - -
=-1.18 NT NT NT
0.19 - - -
0.88 + + +
0.61 + - +
0.22 - - -
0.54 + + +
5.4
6.2
4.7
Hg/Hg2+ = 0.62
7.5
6.1
8.8
7.4
7.5
6.9
6.7
8.3
13.5 4.4
13.3 6.3
16.2 4.1
14.7 7.2
10.6 8.0
10.7 7.9
10.2 9.9
14.1 6.0
14.4 6.4
10.7 8.0
- E°Ti/Ti2+ = -1.63
9.5 10.6
9.8 10.9
13.0 6.2
12.2 5.8
12.0 8.0
13.7 7.3
13.9 6.1
13.8 6.3
13.3 5.8
0.10
0.53
0.14
0.29
0.86
0.50
3.94
0.14
1.14
1.00
1.56
0.27
1.30
0.26
0.27
1.31
1.96
1.82
1.07
0.75
1.78
4.07
1.89
1.38
0.38
0.83
0.40
1.07
0.76
0.28
+ + +
NT NT NT
+ - +
+ - +
+ - +
- + +
+ + +
+ - +
+ - +
+ - +
+ + +
+ + +
+ - +
NT NT NT
+ - +
+ - +
+ + +
- + +
+ + +
+ + +
- + +
aala2, molecular area/depth2;AE= E(LUMO) - E(HOMO) in eV; diameter, molecular diameter; CR,COM-
PACT ratio = [(a/a2)/(AE- 8)]; COMPACT prediction: C1 from P4501 activation, C2E from P4502E activation,
CO is positive when C1 and/or C2E are positive, NT, nottested. Ofthe 44 chemicals, 4 are metals/polymers
and 4were nottested in rodent assay. Original designation as positive, but calculation based on new
structure gives negative.
bOriginal designation as positive, but calculation based on new structure gives negative.
carcinogens by the use of combined data
from structure alert, chronic toxicitystudies,
and theAmes test (22.
Ifthe metal ion redox potentials for the
inorganic compounds are included with
the COMPACT and Hazardexpert data,
chemical no. 16 has a high redox potential
indicative ofrodent carcinogenicity, which
enhances the concordance between pre-
dicted and observed carcinogenicity to
(32/37) 86%.
Evaluation ofIndividual Chemicals
1. Amphetamine. This compound is nega-
tive for P4501 in COMPACT. With a
molecular diameter of 6.5 and the high
value ofAE, there is little likelihood of its
interaction with CYP2E with the genera-
tion of oxygen radicals. Amphetamine is
negative in all segments of the rodent
assay, hence, there is concordance with
COMPACT.
2. Naphthalene. Naphthalene is posi-
tive in COMPACT for both CYPI and
CYP2E, but since naphthalene has only
two fused aromatic rings and does not con-
tain a bay region, metabolic activation is
weak. The compound forms an epoxide
that is cytotoxic, but it is readily conjugat-
ed with glutathione and is hydrolyzed by
epoxide hydrolase (23). There is some evi-
dence from the rodent assay of carcino-
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Rodent Concordance
carcinogenicity COMPACTv. COMPACTv.
MR/FR MM/FM Overall
NE/NE
NT
EE/NE
NE/NE
NE/NE
NE/NE
NE/NE
NE/NE
NT
NE/NE
NE/EE
INC
INC
SE/NE
NT
SE/EE
NE/NE
INC
NE/NE
EE/NE
EE/NE
SE/EE
NE/EE
NE/NE
NT
NE/SE
NE/NE
CE/CE
SE/NE
SE/SE
EE/NE
NE/NE
NE/EE
INC
EE/EE
CE/CE
CE/CE
SE/EE
CE/CE
CE/CE
EE/NE
NT
CE/CE
CE/CE
NE/NE
NE/SE
NE/NE
NE/NE
NE/NE
EE/NE
EE/EE
NE/NE
NE/NE
NE/NE
SE/NE
INC
INC
NE/SE
NE/NE
EE/NE
SE/SE
INC
NE/NE
SE/SE
NE/CE
SE/NE
NE/NE
NE/NE
NE/NE
NE/NE
NT
EE/EE
CE/CE
SE/NE
NE/NE
SE/NE
NE/NE
INC
NT
NT
NT
SE/CE
CE/CE
NT
NE/NE
EE/NE
CE/SE
CE/CE
+
NT
NT
+
+
+
COMPACT
NT
+
NT
+
+
+
carcinogenicity
NT
11
NT
0
1
NT
I
0
0
NT
NT
NT
NT
0
NT
1
1
0
1
1
1°
l
l
l
NT
NT
l
l
l
1
1
Ames
NT
0
NT
0
1°
1
NT
1
0
0
1
0
1
0
1
NT
0
0
11
NT
0
1
1
0
1
1°
1
1
0
0
NT
1
1
1
1°
1
1
aMutagenicity, Salmonella assaywith/without activation; carcinogenicity, rodent assay: MR, male rat; FR,
female rat; MM, male mouse; FM, female mouse; 1 positive out of4 segments ofthe rodent assay is taken
as +; CE (clear evidence) and SE (some evidence) are regarded as +, EE (equivocal evidence) is regarded
as +/-, NE (no evidence) is regarded as -; INC, inconclusive. COMPACT, COMPACT predictions from Table
1; concordance: 1 for correct, 0for incorrect; NT, nottested. Mutagenicity and rodent carcinogenicity
data from Ashby and Tennant(19,20).
bCompounds 31, 33, and 42 are regarded as weak positives/equivocal positives based on pathology
reports.
genicity in the female mouse, but no data
are available for either sex of rat.
Concordance between COMPACT and
carcinogenicity is thus considered to be
positive.
3. Polysorbate 80. This compound was
not examined by COMPACT due to its
polymeric nature.
4. Promethazine. Promethazine is posi-
tive in COMPACT, primarily due to its
low AEvalue; it does not exhibit high pla-
narity due to a bulky side chain and the
combination of sulfur and nitrogen het-
eroatoms in the ring system, which
becomes V-shaped. Consequently, it is
unlikely to be a good P4501 substrate or
inducer. Promethazine is negative in all seg-
ments of the rodent assay; consequently,
there is no concordance with COMPACT.
5. Resorcinol This compound is not a
likely P4501 substrate (CR = 0.70) because
it has a relatively high AEvalue (15.7) and is
readily conjugated. Although the COM-
PACT ratio would suggest that it would be
equivocally positive, in the original graphical
analysis it was clearlynegative (18). Since the
molecular diameter of resorcinol is 5.6, and
its AE is 15.7, the COMPACT prediction
for CYP2E1 is also negative. Resorcinol is
negative in the rodent assay, so the COM-
PACT analysis is in concordance with the
biological data. Hazardexpert predicts that
this compoundwould be mutagenic.
6. y-Butyrolactone. This compound is
negative in COMPACT for P4501, and
although it has a diameter characteristic ofa
P4502E substrate, its high AEvalue miti-
gates against ROS production and carcino-
genicity. A negative finding in the rodent
assay, with the exception of equivocal evi-
dence for carcinogenicity in the male mouse,
accords with the COMPACT prediction,
but Hazardexpertpredicts mutagenicity.
7. Manganese sulfate. The relatively
low redox potential of manganese
(Mn/Mn = -1.18 V) implies that this
compound is unlikely to elicit overt rodent
toxicity. This may explain the low inci-
dence of carcinogenicity, which is seen
only in mice.
8. Chloracetic acid. This compound is
negative in COMPACT for both P4501
and P4502E specificity, and this negative
COMPACT prediction is in accordance
with the rodent study.
9. p-Nitrophenol. The high molecular
planarity ofthis compound predicts a posi-
tive for P4501, and the low diameter, cou-
pled with a relatively low AE, clearly pre-
dicts a positive for P4502E. This nitrophe-
nol is known to be an excellent substrate
for UDP glucuronyl transferase (24) and
for P4502E, so it is readily conjugated
with glucuronic acid, readily hydroxylated,
and eliminated due to its high polarity.
These factors may explain the negative
result in the rodent assay, although the
compound was only tested in the mouse.
Concordance with COMPACT is there-
fore negative. However, the Hazardexpert
prediction is that the chemical would be a
strong carcinogen.
10. Tricresylphosphate. This chemical
is predicted positive in COMPACT for
P4501. Since the rodent tests are all nega-
tive, there is no concordance between the
biological assay and COMPACT predic-
tion. Hazardexpert predicts that the com-
pound would be aweak carcinogen.
11. o-Benzyl-p-chlorophenol. The
COMPACT prediction for this chemical is
negative for both C1 and C2E. Evidence of
carcinogenicity in 1/4 segments of the
rodent assay indicates lack of concordance
with COMPACT prediction. Hazard-
expert also predicts mutagenicity.
12. 2,2-bis(BromomethIyl)-1,3-propane-
diol. This chemical is equivocal for both
P4501 and P4502E in the COMPACT
prediction and is therefore rated a weak
positive. The rodent tests are incomplete,
so concordance cannot be evaluated.
Hazardexpert predicts teratogenicity but
not carcinogencity.
13. t-Butanol COMPACT is negative
for P4501 specificity, and although the
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Ames
mutagenicity
-1+5S9
_I_
_I_
_I_
_I_
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_I_
_I_
_I_
_I_
_I_
_I_
-I-
+l-
NT
_I_
+I+
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-I-
+I+
+I+
_I_
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_I_
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2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31b
32
33b
34
35
36
37
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39
40
41
42b
43
44
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Table 3. Hazardexpert predictions for NTP chemicals
Chemical
1. Amphetamine
2. Naphthalene
3. Polysorbate 80
4. Promethazine
5. Resorcinol
6. y-Butyrolactone
7. Manganese sulphate
8. Chloracetic acid
9. p-Nitrophenol
10. Tricresyl phosphate
11. o-Benzyl-p-chlorophenol
12. 2,2-Bis(bromomethyl)-
1,3-propanediol
13. t-Butyl alcohol
14. 3,4-Dihydrocoumarin
15. Ethylene glycol
16. Mercuric chloride
17. Methyl phenidate
18. Theophylline
19. 4,4'-Thiobis(6-t-butyl-m-cresol)
20. Triamterene
21. Diphenylhydantoin
22. Pentachloroanisole
23. Chloramine
24. 4'4-Diamino-2-2'-stilbene-
disulfonic acid
25. Methyl bromide
26. p-Nitrobenzoic acid
27. Sodium azide
28. Tris(2-chloroethyl)phosphate
29. Cl Direct blue 218
30. Cl Pigment red 3
31. Cl Pigment red 23
32. 2,4-Diaminophenol
33. 4-Hydroxyacetanilide
34. Salicylazosulfapyridine
35. Titanocene dichloride
36. Cl Acid red 14
37. Cl Direct blue 15
38. Coumarin
39. 2,3-Dibromo-l-propanol
40. 3,3'-Dimethylbenzidine
41. HC Yellow 4
42. p-Nitroaniline
43. o-Nitroanisole
44. 1,2,3-Trichloropropane
logP
1.97
3.30
3.97
0.97
0.27
-0.37
1.24
17.32
4.41
0.21
0.78
1.60
-1.94
2.17
-0.20
8.30
-1.42
3.33
5.79
1.93
2.66
0.97
1.49
1.12
0.67
11.84
8.27
8.11
-0.58
5.80
16.00
13.03
1.81
0.42
2.94
-0.89
0.73
1.83
1.56
NP, not predicted; NT, nottested.
aToxicity predictions: + = carcinogenic, - =
Structure alert
None
None
NP-polymeric
None
Phenolic
Lactone
NP-inorganic
Carboxyl
Nitroaromatic
Organophosphate
Phenolic
Bromomethyl
Hydroxymethyl
Lactone
Hydroxymethyl
NP-inorganic
Carboxyl
None
Phenolic
Amino polyaromatic
None
Polyhaloaromatic
None
Aromatic amine
Bromomethyl
Nitroaromatic
None
Organophosphate
Azoaromatic
Azoaromatic
Azoaromatic
Aromatic amine
Azoaromatic
NP-inorganic
Azoaromatic
Azoaromatic
a,B3-Unsaturated ester
Ethyl dihalide
Aromatic amine
Nitroaromatic
Nitroaromatic
Nitroaromatic
Ethyl dihalide
Prediction of
carcinogenicitya
NT
NT
NT
NT
+
noncarcinogenic.
diameter indicates a P4502E substrate, ROS
generation is unlikely as AEis too high. The
chemical is known to exhibit specificity for
P4502E, which confirms the computer pre-
diction, but COMPACT predictions for
both Cl and C2E are negative. As the rodent
data are incomplete, concordance cannot be
evaluated. Hazardexpert predicts terato-
genicity but not carcinogenicity.
14. 3,4-Dihydrocoumarin. The com-
pound is not likely to be P4501 selective
(CR = 0.53) but is positive for P4502E. It
could also result in ring-opening after
being metabolized, giving rise to an entity
with potential for peroxisome prolifera-
tion. The overall COMPACT prediction
(C) is positive, which accords with the
rodent assay where there is evidence for
carcinogenicity in 2/4 segments.
Hazardexpert predicts mutagenicity.
15. Ethylene glycol. This chemical is
negative for both P4501 and P4502E,
which is in accord with the negative mouse
data; no data for rat are yet available.
Hazardexpert predicts teratogenicity but
not carcinogenicity.
16 Mercuric chloride. The high redox
2+ potential (Hg/Hg = +0.62 v) predicts
that this chemical would be positive in the
rodent assay, which agrees with the estab-
lished biological data.
17. Methylphenidate. COMPACT
predictions for this chemical are negative
for both P4501 and P4502E. Rodent data
show evidence of carcinogencitiy in 2/4
segments in the mouse. Thus, there is no
concordance between COMPACT and the
rodent assay. Hazardexpert predicts that
this chemical would be teratogenic but not
carcinogenic.
18. Theophylline. The chemical is posi-
tive in COMPACT for both P4501 and
P4502E and is known to exhibit specificity
for P4501. However, because the rodent
tests are incomplete, it is not possible to
establish concordance at this stage.
19. 4,4'-Thiobis(6-t-butyl m-cresol).
This compound is borderline in COM-
PACT for P4501 and negative for P4502E
and is therefore considered unlikely to be a
carcinogen. In the rodent assay, this com-
pound is negative, which is in concordance
with the COMPACT prediction.
20. Triamterene. COMPACT clearly
predicts a positive for P4501, and N-
hydroxylation by P4501A2 would give rise
to a nitrenium ion that could interact irre-
versibly with DNA. The rodent assay
agrees with this for both segments of the
mouse data, although the rat study is
equivocal. It is considered that COM-
PACT prediction is in concordance with
the biological assay for this compound.
Hazardexpert also predicts carcinogenicity.
21. Diphenylhydantoin (phenytoin).
Phenytoin is negative for both P4501 and
P4502E in COMPACT, and there is sub-
stantial biochemical evidence that it is
metabolized by P4502B and C. Phenytoin
is a known teratogen, but predictions for
carcinogenicity are negative for both
COMPACT and Hazardexpert. There is
evidence ofcarcinogencity in 1/4 segments
(female mouse) of the rodent assay.
Therefore, there is no concordance between
the COMPACT prediction and the find-
ings in the rodent assay.
22. Pentachloroanisole. Pentachloro-
anisole is positive in COMPACT for
P4501 only and may interact with the Ah
receptor (involved in the induction of
P4501A) because there is some degree of
structural similarity with TCDD. This
prediction of carcinogenicity accords with
the positive results obtained in the rodent
assay. Hazardexpert predicts weak carcino-
genicity.
23. Chloramine. Chloramine is posi-
tive for P4501 in COMPACT and was
hence predicted positive. Evidence for car-
cinogenicity in the rodent assay is largely
negative, therefore no concordance is
shown with the COMPACT prediction.
However, this chemical is known to under-
go rapid decomposition in solution and to
be readily eliminated due to its polarity.
24. 4,4-Diamino-2,2'-stilbenedisul-
fonic acid. This chemical is positive for
P4501 in COMPACT, but it is probably
readily eliminated due to the two sulfonic
acid groups, which are both polar and ion-
ized at physiological pH. The rodent car-
cinogenicity data are negative, so there is
no concordance with the COMPACT pre-
Volume 103, Number2, February 1995 181Table 4. Concordance of rodent carcinogenesis bioassaywith COMPACT plus Hazardexpert
Rodent
carcinogenesis COMPACT (CO) Hazardexpert Combined b
Compound assay prediction prediction concordance
1. Amphetamine - - - 1
2. Naphthalene + + - 1
3. Polysorbate 80 - NT NT NT
4. Promethazine - + - 0
5. Resorcinol - - - 1
6. y-Butyrolactone - - - 1
7. Manganese sulphate - NT NT NT
8. Chloracetic acid - - - 1
9. p-Nitrophenol - + + 0
10. Tricresyl phosphate - + + 0
11. o-Benzyl-p-chlorophenol + - - 0
12. 2,2-Bis(bromomethyl)- NT + - NT
1,3-propanediol
13. t-Butyl alcohol NT - - NT
14. 3,4-Dihydrocoumarin + + - 1
15. Ethylene glycol - - - 1
16. Meruric chloride + NT NT NT
17. Methylphenidate + - - 0
18. Theophylline NT + - NT
19. 4,4'-Thiobis(6-t-butyl-m-cresol) - - - 1
20. Triamterene + + + 1
21. Diphenylhydantoin + - - 0
22. Pentachloroanisole + + + 1
23. Chloramine - + - 1
24. 4,4'-Diamino-2,2'-stilbene- - + - 0
disulfonic acid
25. Methyl bromide - + - 0
26. p-Nitrobenzoic acid + + + 1
27. Sodium azide - - - 1
28.Tris(2-chloroethyl)phosphate + - + 1
29. Cl Direct blue 218 + + + 1
30. Cl Pigment red 3 + + + 1
31. Cl Pigment red 23 + + + 1
32. 2,4-Diaminophenol + + - 1
33. 4-Hydroxyacetanilide + + - 1
34. Salicylazosulfapyridine NT + + NT
35. Titanocene dichloride + NT NT NT
36. Cl Acid red 114 + + + 1
37. Cl Direct blue 15 + + + 1
38. Coumarin + + + 1
39. 2,3-Dibromo-l-propanol + + + 1
40. 3,3'-Dimethylbenzidine + + - 1
41. HCYellow4 - - + 1
42. p-Nitroaniline + + + 1
43. o-Nitroanisole + + + 1
44.1,2,3-Trichloropropane + + + 1
aRodent overall carcinogenicity data and overall COMPACT prediction (CO = C1+C2H) are from Tables 1
and 2.
bConcordance of COMPACT plus Hazardexpertwith rodent carcinogenesis assay. Concordance = 1 for
correct; 0 for incorrect; NT, nottested.
diction. Hazardexpert predicts teratogenic-
ity but not carcinogenicity.
25. Methyl bromide. COMPACT pre-
dicts P4502E specificity for this compound,
and there is biochemical evidence to support
this prediction. The mouse bioassay shows
no carcinogenicity; no data are available for
rat. The lack of P4501 specificity accords
with the rodent assay, but there is no con-
cordance between the prediction ofP4502E
activitybyCOMPACT and lackofevidence
of carcinogenicity in the mouse bioassay.
Hazardexpert predicts mutagenicity.
26. p-Nitrobenzoic acid. p-Nitro-
benzoic acid is positive in COMPACT for
P4501 and for P4502E but is rapidly
metabolized by reduction and conjugation,
probably resulting in little carcinogenicity.
The rodent assay shows some evidence of
carcinogenicity in female rat only (1/4 seg-
ments), which is in concordance with the
COMPACT prediction. Hazardexpert pre-
dicts strong carcinogenicity. The p-car-
boxyl group, being electron withdrawing,
will stabilize the nitrenium ion formed
during metabolism of the nitro group,
which contrasts withp-nitrophenol (no. 9)
where the p-hydroxyl group is electron
donating, and destabilizes the nitrenium
ion so that carcinogenicity does not result.
27. Sodium azide. Sodium azide is a
direct-acting mutagen. The related com-
pound, hydrazoic acid, was negative for
P4501 in COMPACT. Although having the
structural criteria for P4502E, hydrazoic acid
is unlikely to generate ROS (AE = 16.2).
Thus, the predictions C1 and CE for COM-
PACT are negative, in concordance with the
ratstudywhich showed no carcinogenicity.
28. Tris(2-chloroethyl)phosphate.
COMPACT is negative for both P4501
and P4502E, but it is probably direct-act-
ing via the 2-chloroethyl (mustard) group.
Clear evidence of carcinogenicity in the
mouse means that there is no concordance
with COMPACT. Hazardexpert predicts a
weak carcinogen.
29. CIDirect blue 218. This chemical
is positive for P4501 in COMPACT and is
likely to undergo microbial azo reduction
to form planar (carcinogenic) metabolites.
The COMPACT prediction is in agree-
ment with the rodent assay, which was
clearly positive. Hazardexpert predicts
marked carcinogenicity.
30. CI Pigment red 3. Another azo
compound like the previous chemical, CI
pigment red 3 is similarly predicted by
COMPACT to be positive for P4501 and
therefore carcinogenic. This prediction of
carcinogenicity by COMPACT is in agree-
ment with the rodent assay which shows
carcinogenicity in 3/4 segments.
Hazardexpert predicts strong carcinogenic-
ity.
31. CIPigment red23. This azo dye is
also P4501 positive in COMPACT, but
there is equivocal evidence ofcarcinogenic-
ity in only 1/4 segments in the rodent
assay, probably due to the polarity of the
compound and its ease of detoxication.
However, following further details of the
rodent pathology, this chemical is consid-
ered to be a weakly positive carcinogen.
COMPACT prediction is therefore in con-
cordance with the rodent assay. Hazard-
expert predicts strong carcinogenicity.
32. 2,4-Diaminophenol. 2,4-Diamino-
phenol is positive for both P4501 and
P4502E in COMPACT and therefore is
predicted to be a carcinogen. In the rodent
assay there is evidence ofcarcinogenicity in
only 1/4 segments, probably due to exten-
sive detoxication by metabolic conjugation.
Therefore, there is concordance between
the COMPACT prediction and the biolog-
ical assay. Hazardexpert predicts terato-
genicity but not carcinogenicity.
33. 4-Hydroxyacetanilide (aceta-
minophen). The compound is weakly posi-
tive for P4501 and P4502E in COM-
PACT, which is in agreement with experi-
mental evidence. However, rodent evi-
dence of carcinogenicity is only weakly
positive, probably because of metabolic
detoxication. Concordance between
COMPACT and the rodent assay is
regarded as positive. Moreover, the positive
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findings for P4501 and P4502E in COM-
PACT are in agreement with the known
lethal hepatotoxicity and nephrotoxicity.
34. Salicylazosulfapyridine. This com-
pound is positive for P4501 in COM-
PACT, and is consequently predicted to be
a carcinogen. The rodent carcinogenicity
tests are incomplete, so it is not possible to
confirm this result, but this drug is known
to be cytotoxic and to cause male infertility
in humans (25). Hazardexpert predicts
high carcinogenicity.
35. Titanocene dichloride. Quanti-
tative structure-activity relationship work
suggests that, on the basis of redox poten-
tial (Ti/Ti2, = -1.63 v), the compound is
unlikely to show overt rodent toxicity.
Rodent carcinogenicity is equivocal.
36. CI Acid red 114. COMPACT
gives a clear indication for P4501 specifici-
ty and a prediction of carcinogenicity.
However, because of its very high polarity
(4 sulfonic acid groups and 2 phenolic
groups), carcinogenicity would not be
exhibited by the parent compound. Azo
reduction leads to the formation of 3,3'-
dimethylbenzidine, which is a known car-
cinogen and is a P4501 substrate by
COMPACT (see compound no. 40).
Hence, this COMPACT prediction ofcar-
cinogenicity agrees with the clear evidence
of carcinogenicity in the rodent assay.
Hazardexpert predicts a strong carcinogen.
37. CIDirect blue 15. This chemical is
structurally related to the previous com-
pound and is also positive in the P4501
COMPACT. As with CI Acid red 114,
carcinogenicity is likely to be mediated by
3,3'-dimethoxybenzidine, the product of
azo reduction cleavage. Clear evidence of
carcinogenicity in the rodent assay shows
concordance with the COMPACT predic-
tion. Hazardexpert predicts a strong car-
cinogen.
38. Coumarin. Coumarin has longbeen
suspected of being a carcinogen. COM-
PACT predicts carcinogenicity from the
specificity ofcoumarin for P4501, which is
in agreement with the carcinogenicity seen
in 3/4 segments of the rodent assay.
Hazardexpert predicts carcinogenicity.
39. 2,3-Dibromo-1-propanoL Although
negative for P4501, COMPACT shows
clear evidence for P4502E specificity and
oxygen radical generation. It is likely, there-
fore, to be a rodent carcinogen; this is in
complete agreement with the carcinogenici-
ty seen in 4/4 segments ofthe rodent assay
in accordance with COMPACT predic-
tion. Hazardexpert predicts carcinogenicity.
40. 3,3'-Dimethylbenzidine. 3,3'-
Dimethylbenzidine is positive for P4501
specificity in COMPACT and was thus
predicted to be carcinogenic. This is in
complete agreement with the carcinogenic-
ity seen in the rat assay; no data are avail-
able for mouse. Hazardexpert predicts ter-
atogenicity but not carcinogenicity.
41. HC Yellow 4. This compound was
originally weakly positive for P4501 in
COMPACT, but the chemical structure
was incorrectly given. A reevaluation ofthe
correct structure revealed that it was nega-
tive in COMPACT, which is in agreement
with the rodent assay that was equivocal in
one segment only and negative in the
remaining three. Hazardexpert predicts
strong carcinogenicity.
42. p-Nitroaniline. p-Nitroaniline is
positive for P4501 and probably P4502E,
and the COMPACT prediction is that it is
carcinogenic. This compound was not
evaluated for carcinogenicity in the rat and
gave an equivocal result in the mouse.
Further detail on the pathology indicates
that it should be regarded as weakly posi-
tive, indicating concordance with the
COMPACT prediction. Hazardexpert pre-
dicts strong carcinogenicity.
43. o-Nitroanisole. o-Nitroanisole is
positive for P4501 and also P4502E in
COMPACT, which predicts its carcino-
genicity. Clear evidence ofcarcinogenicity in
three segments ofthe rodent assay, and some
evidence in the fourth, is in agreement with
the COMPACT prediction. Hazardexpert
predicts strongcarcinogenicity.
44. 1,2,3-Trichloropropane. Although
negative for P4501 specificity, this chemi-
cal is clearly a P4502E substrate with likely
activation to form ROS. This indicates
potential rodent carcinogenicity, which is
in agreement with the rodent assay that
showed carcinogenicity in all four seg-
ments. There is therefore positive concor-
dance between the biological assay and the
COMPACT prediction. Hazardexpert pre-
dicts strong carcinogenicity.
In summary, the concordance ofCOM-
PACT (C) predictions with the rodent car-
cinogenicity assay is 72%, and for COM-
PACT (CO) plus Hazardexpert, the concor-
dance is 86%.
Discussion
At the National Institute ofEnvironmental
Health Sciences international workshop,
Predicting Chemical Carcinogenesis in
Rodents, held in May 1993, the impor-
tance of metabolism and the need for an
understanding of the mechanisms of car-
cinogenicity were emphasized. The key
roles of certain cytochromes P450 in the
metabolic activation ofmany chemical car-
cinogens is well established (12,26), and
these have been addressed in the COM-
PACT study. The COMPACT techniques
are being further developed to take account
ofmore recent developments in the under-
standing ofthe mechanisms oftoxicity and
carcinogenicity. One of the limitations of
COMPACT, that of identifying all direct-
acting carcinogens, can be circumvented by
using a structural alert identifier, such as
Hazardexpert. Structural alert procedures
will also identify those few carcinogenic
chemicals that do not appear to depend on
the cytochromes P450 for activation.
The use of COMPACT parameters
(aid2, AE, molecular diameter) in defining
P450 specificity and P450-mediated toxici-
ty is supported by quantitative structure-
activity relationship evidence for many
series ofcompounds, showing high correla-
tions between one or more COMPACT
parameters, sometimes in combination
with other structural descriptors, and bio-
logical activity such as carcinogenicity,
mutagenicity, P450 induction, and P450-
mediated metabolism (2,3). In particular,
frontier orbital energies have been found to
correlate well with many biological end-
points related to toxicity. The AEparame-
ter, which is an additive combination of
the two frontier orbital energies,
E(HOMO) and E(LUMO), is a measure
ofthe energy required to promote an elec-
tron from the highest occupied molecular
orbital to the lowest unoccupied one, i.e.,
AE = E(LUMO) - E(HOMO). As far as
P450-mediated reactions are concerned,
AE could be a measure of the degree of
interaction between substrate and enzyme
and/or the ability of the substrate to
become oxygenated by the P450.
Furthermore, AE correlates well with the
electron uptake rate constant, ke, for 26
structurally diverse chemicals (R = 0.82).
Therefore, there is some degree ofcomple-
mentarity between COMPACT and the ke
test. The ke test has been shown by others
to be a valuable physical method for the
identification ofchemical carcinogens (27).
The two parameters AE and ke probably
predict the likelihood of interaction
between the test chemical or its metabolite
and DNA; this is generally regarded as
being an electrophilic interaction.
Carcinogenic effects mediated by inter-
action with cellular receptors, such as the
Ah receptor, the peroxisome proliferator-
activated receptor (ppar) and the estrogen
receptor (ER), may also be predicted. We
have modeled the latter two receptors (28)
from their amino acid sequences, enabling
the structural basis ofligand binding inter-
actions to be explored. Although the Ah
receptor has not yet been sequenced,
COMPACT is able to identify its potential
ligands because they are inducers of
cytochrome P4501 and bear molecular
characteristics common to P4501 sub-
strates. Moreover, molecular modeling of
entire P450 proteins associated with xeno-
biotic metabolism has been undertaken,
based on sequence homology with the bac-
terial form of P450, which is of known
crystal structure (29). The putative active
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Table 5. Summary of concordances, sensitivities, and predictivitiesa
Concordance with rodent assay
CYP1 COMPACT (C1) 23/36 = 64%
CYP1 + CYP2E COMPACT(CO) 26/36 = 72%
Hazardexpert alone 25/36 = 70%
COMPACT(CO) plus Hazardexpert 31/36 = 86%
Sensitivity = No. of rodent carcinogens positive in test
No. of rodent carcinogens
Positive predictivity = No. of rodent carcinogens positive in test
No. oftotal positives in test
Negative predictivity = No. of rodent noncarcinogens negative in test
No. oftotal negatives in test
COMPACT Ames test Hazardexpert
Sensitivity 18/24 = 75% 13/24 = 54% 14/24 = 60%
Positive predictivity 18/24= 75% 13/16 = 81% 14/18 = 78%
Negative predictivity 8/13 = 62% 11/26 = 42% 11/21 = 52%
aOfthe total of44 chemicals, 4 (12, 13, 18 and 34) had incomplete rodent carcinogenicity data, and 4were
polymers or inorganic (3, 7, 16, 35), thus leaving a total of36 for evaluation by COMPACT.
sites of these enzymes are considerably
complementary to their specific substrates,
and such studies will inevitably lead to fur-
ther developments in COMPACT.
In conclusion, this study has shown that
original COMPACT, based solely on CYPI
specificity, is 64% predictive of rodent car-
cinogenicity in the 36 chemicals tested.
COMPACT that includes CYP2E specifici-
ty in addition to CYPI specificity improves
the concordance to 72%. This takes into
account the possibility of carcinogenicity
produced directly from the generation of
reactive oxygen species (ROS) mediated by
P4502E and the formation ofreactive inter-
mediates from the activation of the chemi-
cals by these ROS (12). The sensitivity of
COMPACT (CYP1 and CYP2E) is 75%,
and its positive predictivity is 75% (Table
5). Furthermore, structural criteria for other
P450 substrate specificity, and for associated
receptors, should increase the scope of the
technique. However, it would be advanta-
geous to combine COMPACT with a struc-
tural alert program such as Hazardexpert,
especially as this gives the added advantage
ofcalculating logP and pI§ values. We have
shown that such a combination increases
concordance with the rodent assay from
72% to 86% (Table 5). Four out offive of
those chemicals that were incorrectly
assigned by COMPACT in combination
with Hazardexpert were predicted success-
fully by a combination of other methods
(mutagenicity, structural alert, rodent
chronic toxicity data) (22), which indicates
that a battery ofshort term tests could pro-
vide a favorable comparison with rodent
carcinogenicity (19,20,30-32).
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